Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation

Biochemistry

Volumn 48, Issue 26, 2009, Pages 6126-6135

  Ishimaru, Daniella ^a   Ano Bom, Ana Paula D ^a   Lima, Luís Maurício T R ^a   Quesado, Pablo A ^a   Oyama, Marcos F C ^a   De Moura Gallo, Claudia V ^b   Cordeiro, Yraima ^a   Silva, Jerson L ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CONFORMATIONAL CHANGE; CONFORMATIONAL STABILITIES; DNA BINDING; DNA INTERACTION; DNA RECOGNITION; HIGH CONCENTRATION; LOW IONIC STRENGTH; MISFOLDED PROTEINS; MISFOLDING; NUCLEAR PROTEINS; OSMOLYTES; PHYSIOLOGICAL SALT CONCENTRATIONS; PROTEIN STABILITY; SALT CONCENTRATION; TETRAMER; TUMOR SUPPRESSOR PROTEINS; TUMOR SUPPRESSORS;

CONFORMATIONS; GENES; GLYCEROL; IONIC STRENGTH; IONIZATION OF LIQUIDS; NUCLEIC ACIDS; OLIGOMERIZATION; STABILIZATION; TRANSCRIPTION FACTORS; TUMORS;

DNA;

AMYLOID; CORE PROTEIN; GLYCEROL; MONOMER; NUCLEAR PROTEIN; PROTEIN P53; SODIUM CHLORIDE; TETRAMER; TRANSCRIPTION FACTOR; WATER;

ARTICLE; CONFORMATIONAL TRANSITION; DIMERIZATION; DNA BINDING; DNA SEQUENCE; IONIC STRENGTH; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN STABILITY;

ANILINO NAPHTHALENESULFONATES; CONSENSUS SEQUENCE; DNA; FLUORESCENT DYES; GLYCEROL; HUMANS; HYDROSTATIC PRESSURE; LIGHT; OSMOLAR CONCENTRATION; POLYDEOXYRIBONUCLEOTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STABILITY; RECOMBINANT PROTEINS; SCATTERING, RADIATION; SPECTROMETRY, FLUORESCENCE; TUMOR SUPPRESSOR PROTEIN P53; WATER;

EID: 67650078274     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9003028     Document Type: Article

References (62)

1. Prives, C., and Hall, P. A. (1999) The p53 pathway. J. Pathol. 187, 112-126.
2. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307-310.
3. Levesque, A. A., and Eastman, A. (2007) p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?. Carcinogenesis 28, 13-20. (Pubitemid 44942622)
4. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49.
5. Vogelstein, B., and Kinzler, K. W. (1992) p53 function and dysfunction. Cell 70, 523-526.
6. Meek, D. W. (2004) The p53 response to DNA damage. DNA Repair (Amsterdam) 3, 1049-1056.
7. Nagaich, A. K., Appella, E., and Harrington, R. E. (1997) DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J. Biol. Chem. 272, 14842-14849.
8. Riley, K. J., Cassiday, L. A., Kumar, A., and Maher, L. J., 3rd (2006) Recognition ofRNA by the p53 tumor suppressor protein in the yeast three-hybrid system. RNA 12, 620-630.
9. Oberosler, P., Hloch, P., Ramsperger, U., and Stahl, H. (1993) p53- catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 12, 2389-2396. (Pubitemid 23194189)
10. Stros, M., Muselikova-Polanska, E., Pospisilova, S., and Strauss, F. (2004) High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops. Biochemistry 43, 7215-7225. (Pubitemid 38720539)
11. Szak, S. T., and Pietenpol, J. A. (1999) High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. J. Biol. Chem. 274, 3904-3909.
12. Lee, S., Cavallo, L., and Griffith, J. (1997) Human p53 binds Holliday junctions strongly and facilitates their cleavage. J. Biol. Chem. 272, 7532-7539.
13. Wolcke, J., Reimann, M., Klumpp, M., Gohler, T., Kim, E., and Deppert, W. (2003) Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA binding. J. Biol. Chem. 278, 32587-32595.
14. Klein, C., Planker, E., Diercks, T., Kessler, H., Kunkele, K. P., Lang, K., Hansen, S., and Schwaiger, M. (2001) NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276, 49020-49027.
15. Rippin, T. M., Freund, S. M., Veprintsev, D. B., and Fersht, A. R. (2002) Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J. Mol. Biol. 319, 351-358.
16. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355. (Pubitemid 24259959)
17. Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., and Fersht, A. R. (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. U.S.A. 94, 14338-14342.
18. Joerger, A. C., and Fersht, A. R. (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 2226-2242. (Pubitemid 46536643)
19. Kocisko,D. A., Vaillant, A., Lee, K. S., Arnold, K. M., Bertholet, N., Race, R. E., Olsen, E. A., Juteau, J. M., and Caughey, B. (2006) Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 50, 1034-1044.
20. King, D. J., Safar, J. G., Legname, G., and Prusiner, S. B. (2007) Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J. Mol. Biol. 369, 1001-1014.
21. Silva, J. L., Lima, L. M., Foguel, D., and Cordeiro, Y. (2008) Intriguing nucleic-acid-binding features of mammalian prion protein. Trends Biochem. Sci. 33, 132-140.
22. Ishimaru, D., Andrade, L. R., Teixeira, L. S., Quesado, P. A., Maiolino, L. M., Lopez, P. M., Cordeiro, Y., Costa, L. T., Heckl, W. M., Weissmuller, G., Foguel, D., and Silva, J. L. (2003) Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry 42, 9022-9027. (Pubitemid 36935410)
23. Lee, A. S., Galea, C., DiGiammarino, E. L., Jun, B., Murti, G., Ribeiro, R. C., Zambetti, G., Schultz, C. P., and Kriwacki, R. W. (2003) Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant. J. Mol. Biol. 327, 699-709.
24. Higashimoto, Y., Asanomi, Y., Takakusagi, S., Lewis, M. S., Uosaki, K., Durell, S. R., Anderson, C. W., Appella, E., and Sakaguchi, K. (2006) Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry 45, 1608-1619. (Pubitemid 43222105)
25. Rigacci, S., Bucciantini, M., Relini, A., Pesce, A., Gliozzi, A., Berti, A., and Stefani, M. (2008) The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys. J. 94, 3635-3646.
26. Ishimaru, D., Lima, L. M., Maia, L. F., Lopez, P. M., Ano Bom, A. P., Valente, A. P., and Silva, J. L. (2004) Reversible aggregation plays a crucial role on the folding landscape of p53 core domain. Biophys. J. 87, 2691-2700.
27. Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., and Zambetti, G. (1996) Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16, 1126-1137.
28. Selivanova, G., and Wiman,K.G. (2007) Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26, 2243-2254. (Pubitemid 46536645)
29. Paladini, A. A., and Weber, G. (1981) Absolute measurements of fluorescence polarization at high pressures. Rev. Sci. Instrum. 52, 419-427.
30. Wyman, J. Jr. (1964) Linked functions and reciprocal effects in hemoglobin: a second look. Adv. Protein Chem. 19, 223-286.
31. Record, M. T. Jr., Lohman, M. L., and De Haseth, P. (1976) Ion effects on ligand-nucleic acid interactions. J. Mol. Biol. 107, 145-158.
32. Lima, L. M., and Silva, J. L. (2004) Positive contribution of hydration on DNA binding by E2c protein from papillomavirus. J. Biol. Chem. 279, 47968-47974.
33. Ishimaru, D., Maia, L. F., Maiolino, L. M., Quesado, P. A., Lopez, P. C., Almeida, F. C., Valente, A. P., and Silva, J. L. (2003) Conversion of wild-type p53 core domain into a conformation that mimics a hot-spot mutant. J. Mol. Biol. 333, 443-451.
34. Lima, L. M., Foguel, D., and Silva, J. L. (2000) DNA tightens the dimeric DNA-binding domain of human papillomavirus E2 protein without changes in volume. Proc. Natl. Acad. Sci. U.S.A. 97, 14289-14294.
35. Da Poian, A. T., Johnson, J. E., and Silva, J. L. (1994) Differences in pressure stability of the three components of cowpea mosaic virus: implications for virus assembly and disassembly. Biochemistry 33, 8339-8346. (Pubitemid 24241069)
36. Mozhaev, V. V., Heremans, K., Frank, J., Masson, P., and Balny, C. (1996) High pressure effects on protein structure and function. Proteins 24, 81-91. (Pubitemid 26044597)
37. Silva, J. L., Foguel, D., and Royer, C. A. (2001) Pressure provides new insights into protein folding, dynamics and structure. Trends Biochem. Sci. 26, 612-618.
38. Foguel, D., and Silva, J. L. (2004) New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies. Biochemistry 43, 11361-11370. (Pubitemid 39186958)
39. Akasaka, K. (2006) Probing conformational fluctuation of proteins by pressure perturbation. Chem. Rev. 106, 1814-1835.
40. Senear, D. F., Tretyachenko-Ladokhina, V., Opel, M. L., Aeling, K. A., Hatfield, G. W., Franklin, L. M., Darlington, R. C., and Alexander Ross, J. B. (2007) Pressure dissociation of integration host factor-DNA complexes reveals flexibility-dependent structural variation at the protein-DNA interface. Nucleic Acids Res. 35, 1761-1772.
41. Weinberg, R. L., Veprintsev, D. B., Bycroft, M., and Fersht, A. R. (2005) Comparative binding of p53 to its promoter and DNA recognition elements. J. Mol. Biol. 348, 589-596.
42. Joerger, A. C., and Fersht, A. R. (2008) Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582.
43. von Hippel, P. H. (1994) Protein-DNA recognition: new perspectives and underlying themes. Science 263, 769-770. (Pubitemid 24093203)
44. von Hippel, P. H. (2007) From "simple" DNA-protein interactions to the macromolecular machines of gene expression. Annu. Rev. Biophys. Biomol. Struct. 36, 79-105.
45. Nichols, N. M., and Matthews, K. S. (2001) Protein-DNA binding correlates with structural thermostability for the full-length human p53 protein. Biochemistry 40, 3847-3858. (Pubitemid 32280421)
46. Tidow, H., Melero, R., Mylonas, E., Freund, S. M., Grossmann, J. G., Carazo, J. M., Svergun, D. I., Valle, M., and Fersht, A. R. (2007) Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl. Acad. Sci. U.S.A. 104, 12324-12329.
47. Boeckler, F.M., Joerger,A.C., Jaggi, G.,Rutherford, T. J.,Veprintsev, D. B., and Fersht, A. R. (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. U.S.A. 105, 10360-10365.
48. Mohana-Borges, R., Pacheco, A. B., Sousa, F. J., Foguel, D., Almeida, D. F., and Silva, J. L. (2000) LexA repressor forms stable dimers in solution. The role of specific dna in tightening proteinprotein interactions. J. Biol. Chem. 275, 4708-4712.
49. Bell, S., Klein, C., Muller, L., Hansen, S., and Buchner, J. (2002) p53 contains large unstructured regions in its native state. J. Mol. Biol. 322, 917-927.
50. Veprintsev, D. B., and Fersht, A. R. (2008) Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res. 36, 1589-1598.
51. Tafvizi, A., Huang, F., Leith, J. S., Fersht, A. R., Mirny, L. A., and van Oijen, A. M. (2008) Tumor suppressor p53 slides on DNA with low friction and high stability. Biophys. J. 95, L01-L03.
52. Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., and Shakked, Z. (2006) Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22, 741-753. (Pubitemid 43912472)
53. Daniel, I., Oger, P., and Winter, R. (2006) Origins of life and biochemistry under high-pressure conditions. Chem. Soc. Rev. 35, 858-875.
54. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. (1993) Gain of function mutations in p53. Nat. Genet. 4, 42-46.
55. Lang, G. A., Iwakuma, T., Suh, Y. A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., El-Naggar, A. K., and Lozano, G. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872. (Pubitemid 40017691)
56. Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., and Jacks, T. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860. (Pubitemid 40017690)
57. Mizuarai, S., Yamanaka, K., and Kotani, H. (2006) Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor- H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 66, 6319-6326.
58. Bullock, A. N., Henckel, J., and Fersht, A. R. (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245-1256. (Pubitemid 30160617)
59. Klein, C., Georges, G., Kunkele, K. P., Huber, R., Engh, R. A., and Hansen, S. (2001) High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. J. Biol. Chem. 276, 37390-37401.
60. Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rudiger, S., and Fersht, A. R. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. U.S.A. 99, 937-942.
61. Issaeva, N., Friedler, A., Bozko, P., Wiman,K. G., Fersht, A. R., and Selivanova, G. (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. U.S.A. 100, 13303-13307.
62. Proske, D., Blank, M., Buhmann, R., and Resch, A. (2005) Aptamers; basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69, 367-374.